一种新型过氧化物酶体增殖物激活受体α激动剂治疗糖尿病视网膜病变的疗效
本研究通过荧光素酶报告基因实验鉴定出化学结构不同于现有PPARα激动剂的新化合物Y-0452,并在链脲佐菌素诱导的糖尿病大鼠及氧诱导视网膜病变模型中评价其对糖尿病视网膜病变的作用。Y-0452激活PPARα转录活性并上调PPARα表达,抑制人视网膜毛细血管内皮细胞迁移和成管,保护R28细胞、抑制NF-κB信号,在糖尿病大鼠中改善视网膜白细胞淤滞和血管渗漏、保留视网膜功能并减少视网膜细胞死亡,在氧诱导视网膜病变模型中减轻视网膜新生血管。
要点
- Y-0452是化学结构不同于现有PPARα激动剂的新型PPARα激动剂,可激活PPARα转录活性并上调其表达。
- 在糖尿病大鼠中,Y-0452改善视网膜白细胞淤滞和血管渗漏,保留视网膜功能并减少视网膜细胞死亡。
- 在氧诱导视网膜病变模型中,Y-0452减轻视网膜新生血管;作者认为其对糖尿病视网膜病变具有治疗潜力。
核心结论
- Y-0452是一种新型PPARα激动剂,对糖尿病视网膜病变具有治疗潜力。
研究设计与样本
- 体外实验:采用荧光素酶报告基因启动子实验测定PPARα转录活性,用TUNEL评价视网膜前体细胞(R28)凋亡。
- 动物实验:链脲佐菌素注射诱导大鼠糖尿病,用白细胞淤滞实验检查视网膜炎症、通透性实验测定视网膜血管渗漏、视网膜电图(ERG)记录测定视网膜功能、细胞死亡ELISA定量视网膜凋亡。
- 抗血管生成作用在氧诱导视网膜病变(OIR)模型中评价。
主要发现
- 化合物7-氯-8-甲基-2-苯基喹啉-4-羧酸(Y-0452)激活PPARα转录活性并上调PPARα表达。
- Y-0452显著抑制人视网膜毛细血管内皮细胞迁移和成管。
- Y-0452保护R28细胞对抗凋亡,并抑制暴露于棕榈酸的R28细胞中的NF-κB信号。
- 在糖尿病大鼠中,Y-0452改善视网膜白细胞淤滞和血管渗漏,保留视网膜功能并减少视网膜细胞死亡。
- Y-0452在OIR模型中减轻视网膜新生血管。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical studies have shown that peroxisome proliferator-activated receptor alpha (PPARα) agonist fenofibrate has therapeutic effects on diabetic retinopathy (DR). The purpose of this study was to identify a novel PPARα agonist and to evaluate its beneficial effects on DR. METHODS: The transcriptional activity of PPARα was measured by a luciferase-based promoter assay. TUNEL was used to evaluate apoptosis in retinal precursor cells (R28). Diabetes was induced in rats by injection of streptozotocin. Retinal inflammation was examined using leukostasis assay, and retinal vascular leakage was measured using permeability assay. Retinal function was measured using electroretinogram (ERG) recording, and retinal apoptosis was quantified using the cell death ELISA. The anti-angiogenic effect was evaluated in the oxygen-induced retinopathy (OIR) model. RESULTS: A compound, 7-chloro-8-methyl-2-phenylquinoline-4-carboxylic acid (Y-0452), with a chemical structure distinct from existing PPARα agonists, activated PPARα transcriptional activity and upregulated PPARα expression. Y-0452 significantly inhibited human retinal capillary endothelial cell migration and tube formation. The compound also protected R28 cells against apoptosis and inhibited NF-κB signaling in R28 cells exposed to palmitate. In diabetic rats, Y-0452 ameliorated leukostasis and vascular leakage in the retina. In addition, Y-0452 preserved the retinal function and reduced retinal cell death in diabetic rats. Y-0452 also alleviated retinal neovascularization in the OIR model. CONCLUSIONS: Y-0452 is a novel PPARα agonist and has therapeutic potential for DR.
引用
- Deng G, Moran EP, Cheng R, et al. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017. PMID: 28979999. doi:10.1167/iovs.16-21402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。